PDCD1 and cancer: The NOX1/4 inhibitor GKT137831, also known as setanaxib, potentiates immune activity in CD8+ T cells, enhancing their infiltration into cancer-associated fibroblasts and potentially reversing resistance to programmed cell death protein 1 (PD-1)/PD-ligand 1 immunotherapy 106.